YW1128 – 10 mg

Brand:
Cayman
CAS:
2131223-64-6
Storage:
-20
UN-No:
Non-Hazardous - /

YW1128 is an inhibitor of Wnt/β-catenin signaling with an IC50 value of 4.1 nM in a reporter assay.{35719} It decreases protein levels of β-catenin in the presence of the GSK3β inhibitor lithium chloride and increases protein levels of Axin1 in HEK293 cells. YW1128 decreases lipid accumulation and the expression of gluconeogenic and lipogenic genes in Huh7 cells. It decreases the hepatic expression of Wnt target genes, improves glucose tolerance, and prevents body weight increases and hepatic lipid accumulation in mice fed a high-fat diet, but not mice fed normal chow, when administered at a dose of 40 mg/kg every other day for 11 weeks.  

 

Available on backorder

SKU: 27450 - 10 mg Category:

Description

An inhibitor of Wnt signaling (IC50 = 4.1 nM); decreases lipid accumulation and the expression of gluconeogenic and lipogenic genes in Huh7 cells; decreases the hepatic expression of Wnt target genes, improves glucose tolerance, prevents body weight increases and hepatic lipid accumulation in mice fed a high-fat diet, but not mice fed normal chow, at 40 mg/kg every other day for 11 weeks


Formal name: 5-methyl-1-(2-methylphenyl)-N-2-quinolinyl-1H-1,2,3-triazole-4-carboxamide

Synonyms: 

Molecular weight: 343.4

CAS: 2131223-64-6

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals||Research Area|Cell Biology|Cell Signaling|Wnt Signaling||Research Area|Endocrinology & Metabolism|Carbohydrate Metabolism||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Diabetes||Research Area|Endocrinology & Metabolism|Metabolic Diseases|NAFLD & NASH||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Obesity